摘要
目的 分析对慢性心力衰竭患者采用沙库巴曲缬沙坦联合美托洛尔治疗的临床疗效.方法 选择2021年1月1日-2022年6月30日我院收治的115例慢性心力衰竭患者,按照奇偶数将其分为常规组57例与研究组58例.两组分别采用不同的药物治疗方法并比较疗效.结果 研究组治疗后的左心室后壁厚度、左心室射血分数、左心室收缩末期内径、左心室舒张末期内径均优于常规组;呼吸困难、乏力、体液潴留的症状缓解时间均短于常规组;乳酸脱氢酶、肌酸激酶同工酶、心肌肌钙蛋白Ⅰ、脑钠肽指标水平改善均优于常规组,两组上述指标比较差异均有统计学意义(t=10.782、10.660、7.926、6.992、8.964、10.283、9.255、21.650、10.916、16.312、8.610,均 P＜0.05).两组不良反应发生率比较差异无统计学意义(x2=0.171,P＞0.05).结论 沙库巴曲缬沙坦联合琥珀酸美托洛尔治疗慢性心力衰竭的功效显著,有助于心功能的恢复.
Abstract
Objective To analyze the clinical efficacy of sacubitril-valsartan combined with metoprolol in the treatment of chronic heart failure.Methods A total of 115 patients with chronic heart failure were admitted from 1 January 2021 to 30 June 2022,were selected and divided into a conventional group(57 cases)and a study group(58 cases)according to odd and even numbers.The two groups were treated with different medication regimens,and the efficacy was compared.Results The study group showed better outcomes in terms of left ventricular posterior wall thickness,left ventricular ejection fraction,left ventricular end-systolic diameter,and left ventricular end-diastolic diameter compared to the conventional group.The time to relieve symptoms such as dyspnea,fatigue,and fluid retention was shorter in the study group.The levels of lactate dehydrogenase,creatine kinase-MB,cardiac troponin I,and brain natriuretic peptide improved more significantly in the study group than in the conventional group,with statistically significant differences(t=10.782,10.660,7.926,6.992,8.964,10.283,9.255,21.650,10.916,16.312,8.610,all P＜0.05).The incidence of adverse reactions between the two groups showed no statistically significant difference(x2=0.171,P＞0.05).Conclusion Sacubitril-valsartan combined with metoprolol has a significant effect in the treatment of chronic heart failure and contributes to the recovery of cardiac function.
维普
万方数据